Mayo Clinic | Strategic Alliance Partners
Latest from Mayo Clinic
ctDNA-Guided Approaches Reveal Effective Adjuvant Agents in MRD+ CRC
April 07, 2025
Article
Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.
OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025
April 02, 2025
Article
Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.
Mayo Clinic Researchers Identify a Measurable Genetic Mutation as a Significant Predictor of Metastasis and Survival in Pancreatic Cancer
March 31, 2025
Article
A Mayo Clinic study showed that KRAS circulating tumor DNA strongly indicates a higher risk of pancreatic cancer spread and worse survival rates.
Five Under 5: Top Oncology Videos for the Week of 3/23
March 30, 2025
Article
The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.
Dr Tyson on Factors Influencing the Selection of Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
March 25, 2025
Video
Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.
Five Under 5: Top Oncology Videos for the Week of 3/16
March 23, 2025
Article
The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.
Brentuximab Vedotin Combo Adds Another Targeted Option Beyond CD19/CD20 in R/R LBCL
March 19, 2025
Article
Grzegorz S. Nowakowski, MD, discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.
Mayo Clinic Researchers Identify Proteins Linked to Immunotherapy Resistance in Metastatic Colorectal Cancer
March 14, 2025
Article
A discovery by researchers from Mayo Clinic may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer.
Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL
March 13, 2025
Video
Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in relapsed/refractory LBCL.
Advanced Therapies and Innovative Options for Prostate Cancer Care
February 13, 2025
Article
Multidisciplinary treatment addresses all facets of patient health, resulting in personalized prostate cancer treatment plans that optimize outcomes.
Other Key Follicular Lymphoma Data From ASH 2024
February 04, 2025
Video
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.
Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma
February 04, 2025
Video
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma
February 04, 2025
Video
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
CD19 Expression Loss and Tafasitamab in R/R DLBCL
February 04, 2025
Video
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.
Clinical Experience Using Tafasitamab Plus Lenalidomide in DLBCL
February 04, 2025
Video
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.
The Phase 3 inMIND Trial: Tafasitamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma
February 04, 2025
Video
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.
Highlighting Key CML/ALL Data Presented at ASH 2024
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.
Selecting a TKI in Subsequent Lines of Therapy in CML
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.
The Role of Frontline Ponatinib Plus Chemo in Ph+ ALL
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.
Dosing Strategies for Ponatinib in CML and ALL
January 23, 2025
Video
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.